AcceleRET-MTC
11 Apr 2022
AcceleRET-MTC
NCT04760288
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.
Hoffmann-La Roche
Cancer Type | Other |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 12 years and older |
Sex | All |
Tumour Stream | Thyroid |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2022-07-01 |
Anticipated End Date | 2028-04-15 |
Hospital | Icon Cancer Centre Adelaide |
---|---|
Clinical Trial Coordinator | Sue Yeend |
sue.yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Dr Gonzalo Tapia Rico |
Recruitment Status | Not Yet Recruiting |
Keep up to date with the latest news and breakthroughs